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Abstract
Background: Malaria is the leading cause of morbidity and mortality in post-conflict Burundi. To counter the
increasing challenge of anti-malarial drug resistance and improve highly effective treatment Burundi adopted
artesunate-amodiaquine (AS-AQ) as first-line treatment for uncomplicated Plasmodium falciparum malaria and oral
quinine as second-line treatment in its national treatment policy in 2003. Uptake of this policy in the public, private
and non-governmental (NGO) retail market sectors of Burundi is relatively unknown. This study was conducted to
evaluate access to national policy recommended anti-malarials.
Methods: Adapting a standardized methodology developed by Health Action International/World Health
Organization (HAI/WHO), a cross-sectional survey of 70 (24 public, 36 private, and 10 NGO) medicine outlets was
conducted in three regions of Burundi, representing different levels of transmission of malaria. The availability on
day of the survey, the median prices, and affordability (in terms of number of days’ wages to purchase treatment)
of AS-AQ, quinine and other anti-malarials were calculated.
Results: Anti-malarials were stocked in all outlets surveyed. AS-AQ was available in 87.5%, 33.3%, and 90% of
public, private, and NGO retail outlets, respectively. Quinine was the most common anti-malarial found in all outlet
types. Non-policy recommended anti-malarials were mainly found in the private outlets (38.9%) compared to
public (4.2%) and NGO (0%) outlets. The median price of a course of AS-AQ was US$0.16 (200 Burundi Francs, FBu)
for the public and NGO markets, and 3.5-fold higher in the private sector (US$0.56 or 700 FBu). Quinine tablets
were similarly priced in the public (US$1.53 or 1,892.50 FBu), private and NGO sectors (both US$1.61 or 2,000 FBu).
Non-policy anti-malarials were priced 50-fold higher than the price of AS-AQ in the public sector. A course of AS-
AQ was affordable at 0.4 of a day’s wage in the public and NGO sectors, whereas, it was equivalent to 1.5 days
worth of wages in the private sector.
Conclusions: AS-AQ was widely available and affordable in the public and NGO markets of hard-to-reach post-
conflict communities in Burundi. However greater accessibility and affordability of policy recommended anti-
malarials in the private market sector is needed to improve country-wide policy uptake.
Background
The East African country of Burundi is one of the smal-
lest countries on the continent, with a population of
about 8 million in 2008. Burundi’s health infrastructure
collapsed during the 13-year civil war that ended in
2005. Presently in post-conflict transition, the country is
focussing its efforts in rebuilding its health system and
reducing the public health burden of diseases. Malaria is
the main cause of morbidity and mortality in Burundi,
with an estimated 2.3 million cases and 7,700 deaths in
2006, of which 70% of these deaths were among chil-
dren less than five years of age [1]. In 2003, Burundi
adopted WHO-recommended artemisinin combination
therapy (ACT), specifically artesunate-amodiaquine (AS-
AQ), as effective first-line treatment for uncomplicated
Plasmodium falciparum malaria and oral quinine as sec-
ond-line in the event of treatment failure. This policy
was adopted following the 2000/2001 malaria epidemic
that was heightened by high parasite resistance to chlor-
oquine [2] and sulphadoxine-pyrimethamine.
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Although a new national treatment policy has been
adopted, accessibility as defined by availability, pricing,
and affordability, to these recommended anti-malarial
treatments remains a challenge. A number of studies
have evaluated the implementation of ACT policy and
access to ACT in the public sector of Burundi soon
after policy adoption. After the first nine months of pol-
icy implementation, one community-based study found
AS-AQ was the most common treatment for children
<5 years of age with uncomplicated malaria attending
public sector facilities, but coverage was low and the
prices patients were paying were ten times higher than
the subsidized price [3]. In another report, WHO found
no recorded shortage of AS-AQ at the national level in
the first year of ACT policy implementation, but 60% of
public sector health facilities experienced stock-outs [4].
In addition, 20% of malaria cases were treated with oral
quinine as first-line treatment rather than AS-AQ since
sales of quinine provided more income to support the
provision of services at these facilities under a govern-
ment cost recovery policy. A nationally representative
household survey showed that only 30% of under-fives
who were ill with fever in the preceding two weeks
received any anti-malarial treatment drugs in Burundi
[5]; however, it was not stated whether these were ACT
or not.
Specifically, high anti-malarial pricing is an important
contributing factor to the lack of access to ACT [6]. In
the public and NGO retail sectors, each treatment of
AS-AQ should be available at the government subsi-
dized price of 200 Burundian Francs (FBu - the equiva-
lent of US$0.16). In addition, treatment should be free
for children ≤ 5 years of age. However, it is unknown
whether AS-AQ is truly available at these subsidized
prices. Although AS-AQ should be readily available in
the public sector, it is often more costly in the private
sector. Many patients in Africa use the private sector as
their primary source of medicines with 50% of febrile
episodes reported to be treated in the private sector [7],
where marked-up manufacturer’s selling prices and final
patient range from 56 to 358%, making treatment unaf-
fordable [8]. On average, households in many malaria
endemic countries spend up to 90% of their household
expenditure on medicines [7].
The government of Burundi recently procured new
fixed-dose ASAQ combination tablets to treat uncompli-
cated malaria in order to improve prescribing practices,
patient compliance and reduce the risk of parasite resis-
tance to AS-AQ. This fixed-dose formulation allows AS
and AQ to be taken together in correct proportions in a
simplified three-day dose regimen where the most vul-
nerable population, children under aged five, take only
one tablet per day. Since there are no subsidies in the
private sector, the government is also considering to
market fixed-dose combination ASAQ in the private
sector with prices comparable to those in the public sec-
tor in a bid to increase nationwide affordability (perso-
nal communication with the NMCP of Burundi, 16th
February 2009). Without heavy ACT subsidies in both
the public and private sectors and other interventions,
coverage of effective treatment may not be realized and
will remain low [9].
Access to AS-AQ at the local level in Burundi is
unknown and it is important that the recently procured
fixed-dose ASAQ is effectively distributed to those with
the potential to suffer from uncomplicated P. falciparum
malaria.
The objective of this study was to evaluate access to
national policy anti-malarials, AS-AQ and quinine as
defined by availability, pricing and affordability in the
public, private and NGO retail markets in Burundi.
Results from this study will help inform advocacy cam-
paigns and policy recommendations to improve coun-
try-wide access to new fixed-dose ASAQ to treat
uncomplicated malaria.
Methods
Study area
A cross-sectional survey was conducted from February
to March 2009, in three provinces of Burundi;
Bujumbjura, Bururi, and Kayanza, representing differ-
ent levels of risk for malaria transmission, hyperen-
demic (altitude <1,400 metres), meso-to-hypo endemic
(altitude 1,400-1,750 metres) and areas of no malaria
transmission (altitude >1,750 meters), respectively
(Figure 1). In addition, these provinces were selected
to provide an urban (Bujumbura) and rural (Bururi
and Kayanza) population distribution. The majority of
Burundians live in rural areas with only 9% living in
urban areas [10]
Selection of outlets
For each region, a list of public medicine outlets was
compiled using a database obtained from the Ministry
of Health in Burundi. A two-stage sampling approach
was used to select the medicine outlets. First, from each
of the three selected survey provinces, the major urban
commune with the main public hospital was selected.
Secondly, seven randomly selected public medicine out-
lets that were reachable within a day’s travel from the
main urban commune were selected. A matching num-
ber of private and NGO sector medicine outlets were
selected by identifying one medicine outlet in each sec-
tor that was geographically closest to each public medi-
cine outlet when possible. Private retail outlets were
oversampled in Bujumbura and Bururi since there were
few NGO medicine outlets (four and three, respectively)
to match the number of public outlets. In Kayanza, all
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private (n = 6) and NGO (n = 3) outlets that existed in
the region were sampled.
Survey methodology
Adapted WHO and Health Action International (HAI)
standardized methodologies for surveying medicine prices,
availability, and affordability were used for this survey [11].
Pharmacists or medicine dispensers were recruited to par-
ticipate in the survey and verbal consent was obtained
from those who agreed to participate. For each anti-
malarial found in the medicine outlet on the day of survey,
trained data collectors recorded information on the brand
name (originator and generic), price, manufacturer, and
manufacturing company were recorded, as well as infor-
mation on the medicine package type (loose pills, single
pack, or hospital package), the availability of the anti-
malarial as over-the-counter or prescription, and the num-
ber of anti-malarials sold in the last month. In addition,
data on the medicine retailer’s knowledge regarding WHO
regulations and national anti-malarial treatment guidelines
were collected. The price of the anti-malarial was origin-
ally collected in Burundian francs (FBu), and then
converted to US dollars (US$). At the time of survey, US
$1 was equivalent to 1,240 FBu.
Data analysis
Data from the different sector medicine outlets were ana-
lysed separately and anti-malarials were stratified by treat-
ment with first-line ACT (AS-AQ according to Burundian
national policy and other WHO-recommended ACT), sec-
ond-line quinine, or other non-policy anti-malarials. For
the availability analysis, different dosage strengths of the
same anti-malarial were combined to calculate the overall
availability of that anti-malarial on the day of survey. Med-
ian prices of anti-malarials were computed if there were
≥4 medicines (following WHO-HAI methodology) identi-
fied for each anti-malarial category regardless of dosage or
form; otherwise, the mean was calculated. Anti-malarials
offered for free were not included in the analysis. For com-
parison, the median price ratios (MPR) of the anti-malarial
median price to the current charge for a single treatment
course of AS-AQ in public health facilities were calculated,
except for quinine. The charge for a treatment course of
AS-AQ dispensed in public sector facilities is US$0.16
Figure 1 Malaria transmission zones in Burundi. Source: NMCP Burundi epidemiological service.
Amuasi et al. Malaria Journal 2011, 10:34
http://www.malariajournal.com/content/10/1/34
Page 3 of 9
(200 FBu). Since there is no government subsidized price
for quinine, the MPR of public to private and public to
NGO sectors were calculated.
Affordability was estimated using median anti-malarial
prices and the average per capita annual income (US
$140/per year or US$0.38/day) in Burundi and calculat-
ing the number of days’ wages required to purchase a
course of the anti-malarial [12]. Recently the President
of Burundi declared that malaria treatment would be
free-of-charge for children under five years of age and
pregnant women, however, this policy was not in effect
during the period of the survey [13].
Results
In this study, a total of 70 medicine outlets, of which 24
(34.4%) were public sector hospitals, 36 (51.4%) private
medicine outlets, and 10 (14.3%) NGO medicine outlets
were surveyed in the regions of Bujumbura (n = 29),
Bururi (n = 24), and Kayzanza (n = 17), respectively.
Availability
The survey found anti-malarials stocked at all outlets.
Nearly 90% of public and NGO outlets surveyed
stocked AS-AQ, the recommended first-line treatment
for uncomplicated malaria. However, only one-third of
private outlets had AS-AQ stocked at the time of sur-
vey (Table 1). In all outlet types, the most common
anti-malarial found was quinine and the tablet formu-
lation was more prevalent than the injections. Other
WHO recommended first-line ACTs (artemether-
lumefantrine and dihydroartemisinin-piperaquine) were
found in the private sector although they were not
part of the Burundian anti-malarial policy. Chloroquine
and sulphadoxine-pyrimethamine were not found in
any outlets.
Non-policy anti-malarials (amodiaquine, dihydroarte-
misinin, and halofantrine) were mainly found in the pri-
vate sector (93.3%) and none in the NGO sector. More
than 80% of public and NGO sector medicine outlets
stocked both first-line and second-line policy recom-
mended anti-malarials. In contrast, only one-third of
private medicine outlets carried both first- and second-
line treatment anti-malarials. Among the regions sur-
veyed, availability of both these policy recommended
anti-malarials was highest in the least malaria endemic
area of Kayanza (Table 1). AS-AQ was available in
about half of the outlets and quinine was available in
over 90% of outlets in both Bujumbura and Bururi.
Table 1 Availability of anti-malarials on day of the survey by retail sector and geographical region
Retail sector Geographical region
Public
(n = 24)
% Private
(n = 36)
% NGO
(n = 10)
% Bujumbura
(n = 29)
% Bururi
(n = 24)
% Kayanza
(n = 17)
%
ACT 21 87.5 12 33.3 9 90.0 15 51.7 11 45.8 16 94.1
AS-AQa 21 87.5 12 33.3 9 90.0 15 51.7 11 45.8 16 94.1
Other first-line ACTb - - 2 5.6 - - - - 2 8.3 - -
Quinine 23 95.8 28 77.8 9 90.0 27 93.1 22 91.7 16 94.1
Quinine injection 17 70.8 23 63.9 9 90.0 21 72.4 16 66.7 12 70.6
Quinine tablets 23 95.8 28 77.8 9 90.0 25 86.2 19 79.2 16 94.1
Both quinine injection and
quinine tablets
17 70.8 18 50.0 9 90.0 19 65.5 13 54.2 12 70.6
Non-policy anti-malarials 1 4.2 14 38.9 - - 9 31.0 3 12.5 3 17.6
Amodiaquine - - 1 2.8 - - 0 0.0 1 4.2 0 0.0
Dihydroartemisinin - - 3 8.3 - - 2 6.9 1 4.2 0 0.0
Halofantrine 1 4.2 10 27.8 - - 7 24.1 2 8.3 2 11.8
Overall anti-malarial
availability
23 95.8 28 77.8 9 90.0 27 93.1 22 91.7 16 94.1
AS-AQ only 1 4.2 0 0.0 1 10.0 0 0.0 1 4.2 1 5.9
Quinine only 2 8.3 13 36.1 1 10.0 7 24.1 9 37.5 0 0.0
Non-policy antimalarials only 0 0.0 1 2.8 0 0.0 1 3.4 0 0.0 0 0.0
AS-AQ+quinine 20 83.3 8 22.2 8 80.0 13 44.8 10 41.7 13 76.5
AS-AQ+non-policy
antimalarials
0 0.0 1 2.8 0 0.0 1 3.4 0 0.0 0 0.0
Quinine+non-policy
antimalarials
1 4.2 9 25.0 0 0.0 6 20.7 3 12.5 1 5.9
AS-AQ+quinine+non-policy
anti-malarials
0 0.0 3 8.3 0 0.0 1 3.4 2 8.3 0 0.0
ACT, artemisinin combination therapy; AS-AQ artesunate-amodiaquine (loose combination).
aFirst-line treatment for uncomplicated malaria under Burundi’s national antimalarial policy.
bOther first-line ACT antimalarials recommended by the WHO were identified (artemether-lumefantrine and dihydroartemisinin-piperquine).
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The presence of non-policy anti-malarials was highest in
the most endemic region of Bujumbura.
Medicine prices
Overall, median prices of a treatment course of AS-AQ
tablets, quinine injections, quinine tablets, and other
non-policy anti-malarials were US$0.16, US$0.32, US
$1.61, and US$8.55, respectively. Median prices of AS-
AQ and quinine were lowest in the public sector and
highest in the private sector (Table 2). The median price
of ACT in the NGO sector was the same as the govern-
ment subsidized price in the public sector. Quinine and
non-policy anti-malarials were priced higher than AS-
AQ. Although not part of national policy at the time of
the survey, three public medicine outlets were dispen-
sing free anti-malarials: one was in a prison and two
public sector outlets had received donations.
The highest MPR was non-policy recommended anti-
malarials which was more than 50-fold in both the pub-
lic and private sectors (Table 3). The private sector had
the highest MPR for policy and non-policy anti-
malarials compared to public and NGO sectors.
Figure 2 shows the median prices of anti-malarials
found in the different medicine outlet sectors stratified
by survey region. In general, private retail outlets in all
three regions charged the highest prices for anti-malar-
ials compared to public and NGO outlet types. AS-AQ
was offered at the government subsidized price of US
$0.16 in all public outlets surveyed across the three sur-
vey regions. The cost of AS-AQ in the private outlets
was two-fold higher than the government subsidized
price in Bujumbura and 7.5-fold higher in Kayanza. The
cost of quinine injections was relatively similar in all
three regions but the median price for quinine tablets
was highest in Kayanza.
Affordability
AS-AQ purchased within the public and NGO sectors
were most affordable, representing 0.4 of a day’s wage
(Table 4). Quinine tablets cost four days worth of wages
in all three sectors. The tablet formulation of quinine
was less affordable compared to quinine injections.
Non-policy recommended anti-malarials were least
affordable, costing about one month’s worth of wages.
Discussion
Anti-malarials were accessible in all outlet types sur-
veyed in Burundi. The results of this study showed high
uptake of malaria treatment policy in post-conflict Bur-
undi where nearly 90% of public and NGO outlets
stocked AS-AQ, the recommended first-line treatment
for uncomplicated malaria. Compared to other post-
conflict countries, availability of anti-malarials in public
facilities were 73.3% in Cambodia [14] and 84.2% in the
Democratic Republic of Congo (DRC) [15]. Of the pub-
lic outlets that stocked anti-malarials 88%, 24%, and
97% stocked first-line treatment ACT, respectively. The
relatively high implementation of policy-recommended
ACT may be a result of the government subsidy on AS-
AQ; the relatively small size of the country to support
its capacity to raise awareness of prevention and control
activities and promote access to appropriate diagnosis
and treatment; and the lack of local pharmaceutical
manufacturers which may have limited the number of
anti-malarials in the market. The results from this study
also confirm other reports on the successful ban on the
use of chloroquine and sulphadoxine-pyrimethamine as
first-line treatment for uncomplicated P. falciparum
malaria in Burundi [3].
Although AS-AQ was highly available, quinine was the
most common anti-malarial in all retail sectors. Specifi-
cally, the private sector was four times more likely to
carry quinine only than the public sector with no alter-
native anti-malarial available. This is of concern when
50% of the country’s 126 private pharmacies are located
in Bujumbura alone where malaria is hyperendemic [16]
A number of reasons could account for the dominant
stock of quinine in the private sector. First, private sector
Table 2 Median prices of anti-malarials being sold in the public, private and NGO sector
Public sector Private sector NGO sector
No. of anti-
malarials
Median price
(range) US$
No. of anti-
malarials
Median price
(range) US$
No. of anti-
malarials
Median price
(range) US$
ASAQ 28 0.16 (0.16-0.16) 19 0.56 (0.16-2.82) 15 0.16 (0.08-2.42)
Quinine 53 0.59 (0.03-1.77) 73 1.09 (0.24-3.39) 25 1.19 (0.16-2.58)
Quinine injection 19 0.24 (0.12-0.48) 25 0.36 (0.24-1.61) 9 0.32 (0.16-0.81)
Quinine tablet 34 1.53 (0.03-1.77) 48 1.61 (0.32-3.39) 16 1.61 (0.51-2.58)
Non-policy anti-
malarials
2 8.90 (0.32-11.29)a 19 8.55 (8.35-9.44) 0
ACT, artemisinin combination therapies; US$, United States Dollars.
Anti-malarials that were offered for free (n = 4; 1 ACT, 1 quinine injection, and 2 quinine tablets) were excluded from median price calculations.
aMean was calculated since there were only two other anti-malarials available in the public sector. According to WHO-HAI methods, there should be at ≥4
medicines to calculate the median.
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medicine sellers view selling AS-AQ as unprofitable,
since it is highly subsidized in the public sector and they
are not able to match those prices. Consequently, they
may prefer to stock quinine which they can retail at a
competitive price. Secondly, quinine has been available in
Burundi since the 1940s and is one of the few anti-
malarials manufactured in-country, making it more pop-
ular as an anti-malarial and more easily accessible than
AS-AQ, which is imported. Thirdly, despite WHO
recommendations for other ACT to be adopted as sec-
ond-line, the policy in Burundi as well as in 29 other
African countries continues to be oral quinine monother-
apy as second-line therapy [17], which could possibly be
negatively affecting uptake of AS-AQ as first-line. Finally,
private medicine sellers may not have received adequate
training for malaria treatment and management, as 96%
of public and 90% of NGO sector medicine sellers in this
Table 4 Number of days-wages to afford antimalarials in
the public, private, and NGO sectors
Public sector Private sector NGO sector
AS-AQ 0.4 1.5 0.4
Quinine 1.4 2.9 3.1
Quinine injection 0.6 1.0 0.8
Quinine tablets 4.0 4.2 4.2
Non-policy antimalarials 23.4 22.5 -
AS-AQ, artesunate-amodiaquine.
Table 3 Median price ratio of anti-malarials in public,
private, and NGO sectors
Public
sector
Private
sector
NGO
sector
ASAQa 1.0 3.5 1.0
Quinine Refb 2.1 2.0
Quinine injection Refb 1.5 1.3
Quinine tablets Refb 1.1 1.1
Non-policy anti-
malarialsa
55.6 53.4 -
ACT, artemisinin combination therapies.
aMedian price ratio calculated based on government subsidized price of AS-
AQ (US$ 0.16).
bMedian price ratios were calculated using the public sector price as reference
for quinine since there is no government subsidized price: US$ 0.59 for
quinine, US$ 0.24 for quinine injection, US$ 1.53 for quinine tablets.
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study were familiar with the indication of ACT use as
being for uncomplicated malaria, compared to 39% in the
private sector.
Although familiarity was lower for indication for use
of quinine in cases of complicated malaria across all
three sectors, it was the lowest in the private sector
(58.3% in the public, 40% in the NGO, and 25% in the
private, respectively). Since the mission hospitals in the
NGO sector facilities receive government support, they
honour the same policy for anti-malarials and have in
effect received adequate training and incentives to dis-
pense ACT, whereas the private sector does not have
this incentive. Similar to the NGO sector, the private
sector needs to engage in the ACT implementation pro-
cess and be provided with adequate training to ensure
correct dispensing of anti-malarials as well as sufficiently
stocking ACT in their facilities.
Alarmingly, several non-policy anti-malarials (amodia-
quine, dihydroartemisinin, and halofantrine) were identi-
fied, which were present almost exclusively in the
private sector. Specifically, halofantrine was available in
over one-quarter of private sector outlets without pre-
scription, which is a cause for concern given the associa-
tion of adverse cardiovascular effects with this drug [18]
and the potential for cross-resistance with lumefantrine
(LUM) and mefloquine (MQ) [19]. This could lead to
devastating effects on the possibility of future distribu-
tion of ACT containing lumefantrine or mefloquine in
Burundi. The presence of these non-policy anti-malarials
requires more effective measures to counter price gou-
ging, smuggling, and counterfeiting if widespread distri-
bution of new fixed-dose AS-AQ is to be achieved [20].
Besides identifying other non-policy anti-malarials
being highly prevalent in the private sector, they were
also highly prevalent in the region of Bujumbura, the
most endemic malaria transmission zone in Burundi. In
the high altitude region of Kayanza, the high availability
of AS-AQ compared to non-policy anti-malarials may
reflect the disincentives in distributing drugs to these
hard-to-reach communities other than government
regulated anti-malarials. In addition, since Bujumbura is
the capital city, the high concentration of private outlets
carrying non-policy anti-malarials is not surprising since
accessibility to imports is much easier in this urban area
compared to the other two rural regions in this study.
Also, retailers may be more likely to inflate prices since
persons of higher socioeconomic status tend to live in
urban areas [6,21] and are more likely to be able to
afford them.
Since the non-profit NGO sector is supplied with AS-
AQ by government and adheres to the subsidy policy, it
is not surprising that the pricing of ACT was found to
be similar in the public and NGO sectors. As compared
to the DRC, AS-AQ in Burundi is affordable (US$3.20
vs. US$0.16) [15], owing to the government’s effort to
subsidize the ACT price. However, the price differential
between the NGO and public sectors for second-line
treatment medicines was similar to that between the pri-
vate and public sector, highlighting the need to consider
the same affordable pricing regime for not only first-line
treatment but also second-line treatment. Given the 3.5-
fold price differential of AS-AQ in the private sector
compared to the public sector, there is a need to make
the pricing of ACT in the private sector comparable to
that in the public sector. Innovative financing mechan-
isms should be considered to incentivize the private sec-
tor towards retailing of ACT, such as what has been
done in neighbouring Rwanda [22].
Although AS-AQ appears to be affordable in the pub-
lic sector, it still costs nearly half a day’s wages in Bur-
undi, and in the private sector, the cost is 1.5 days
worth of wages. Although substantial progress has been
made to make AS-AQ available in the public health sys-
tem of Burundi, it is clear that those who seek treatment
in the private sector are less likely to access ACT, but
they will continue to purchase non-policy recommended
and potentially harmful or ineffective anti-malarials, or
use the cheaper quinine monotherapy. This is of con-
cern, as it is known that most patients seek treatment in
the private sector rather than the public sector given the
long distance to travel to, long waiting times at, and
poor availability of drugs in the public sector [23].
Further study is needed to evaluate the role of the pri-
vate sector in providing treatment for patients in Bur-
undi, so that an effective evidence-based intervention
could be considered to effectively increase AS-AQ
accessibility.
There are several limitations in this study. Firstly,
although the study objective was not to evaluate the fac-
tors determining the price of anti-malarials, the study
lacked comparator drugs (i.e. other essential medicines)
with the anti-malarials evaluated, which made it difficult
to understand whether price variations found reflect the
general prices of all drugs distributed in the retail outlet
or the findings were specific to the class of anti-
malarials. For example, if the price mark-ups of AS-AQ
were significantly higher than other essential medicines,
it would be important to understand and address the
factors that influence these retail price gaps. Secondly,
although we evaluated the availability of AS-AQ and
other anti-malarials, it remained unclear which specific
anti-malarial was dispensed to patients as some private
medicine outlets stocked up to 10 brands of medicines.
It would be relevant to conduct a “mystery shopper”
survey in order to evaluate any potential bias that might
have arisen from directly questioning the medicine dis-
pensers on their knowledge and practice. Thirdly, the
availability of anti-malarials should be interpreted with
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caution since it is unclear how the selection of outlets
within one day’s travel from the main urban public out-
let in the region and the disproportionate distribution of
medicine outlets sampled in the private and NGO sec-
tors might have under- or over-estimated the accessibil-
ity of AS-AQ and other anti-malarials. It is possible that
in hard-to-reach rural areas, ACT may not offer a prof-
itable market for the private sector since it may require
a more complicated distribution chain from the supplier
to the retail outlet [21].
Conclusions
Preliminary results of this study prompted a meeting
with a panel of experts to convene in September 2009,
and proceedings from this meeting have been published
[24]. The high availability of national policy recom-
mended AS-AQ in the public and NGO sector outlets
support the capacity of these two sectors to adopt policy
into practice and gives high promise in the successful
implementation of fixed-dose ASAQ in Burundi. How-
ever, the results also confirm studies in Africa, where
there is an ever-increasing role of the private sector
market in having a large impact on ACT policy imple-
mentation [25-27]. The MoH of Burundi is taking steps
to improve accessibility of AS-AQ by considering similar
pricing for fixed-dose ASAQ in both the public and pri-
vate sector. However, the challenge remains in engaging
with the private sector to make AS-AQ and other policy
recommended anti-malarials widely available in their
outlets and at an affordable price. Innovative strategies
like the Global Fund’s Affordable Medicines Facility-
Malaria (AMFm) initiative are being piloted and
evaluated and are aimed at subsidising high quality anti-
malarials at the manufacturer level in both the public
and private sectors [28,29]. If successful, there is the
potential to increase widespread access to affordable
ACT, bridge the gap between the public and private sec-
tors, and reduce the use of inappropriate treatments.
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